Disease Overview：Malignant Melanoma（MM）
Malignant melanoma is an aggressive form of skin cancer arising from melanocytes—the pigment-producing cells in the epidermis and mucosal membranes. It accounts for the majority of skin cancer-related mortality despite representing only about 1% of all skin cancers. Risk factors include intense intermittent UV exposure, fair skin phenotype, numerous atypical nevi, and genetic predisposition (e.g., CDKN2A mutations). Clinical presentation varies but commonly includes asymmetrical, irregularly bordered, multicolored, enlarging pigmented lesions—often assessed using the ABCDE criteria. Staging follows the AJCC TNM classification, with prognosis heavily dependent on Breslow thickness, ulceration status, mitotic rate, and nodal or distant metastasis. Early-stage disease is primarily managed by wide local excision; advanced cases may require sentinel lymph node biopsy, adjuvant immunotherapy (e.g., anti-PD-1 agents), targeted therapy (BRAF/MEK inhibitors), or radiotherapy.
China offers compelling advantages for malignant melanoma care: leading dermatologic oncology centers—such as Peking University First Hospital and Fudan University Shanghai Cancer Center—boast multidisciplinary teams with extensive experience in complex melanoma resection, micrographic surgery, and systemic therapy sequencing. State-of-the-art PET-MRI hybrid imaging, next-generation sequencing for BRAF/NRAS/KIT profiling, and access to globally approved immunotherapies—including nivolumab, pembrolizumab, and dabrafenib/trametinib—are standard. Five-year survival rates for Stage III patients treated at top-tier institutions align closely with U.S. and EU benchmarks, supported by robust clinical outcome registries. Crucially, treatment costs—including genomic testing, biologics, and surgical intervention—are typically 40–60% lower than in the U.S. or Western Europe, without compromising quality or regulatory oversight (NMPA-approved protocols).
As a dedicated medical tourism agency, we facilitate seamless international patient journeys: verifying hospital accreditation, coordinating specialist consultations, securing priority appointments, managing visa support, and providing transparent, itemized cost estimates upfront. Our bilingual case managers accompany patients throughout diagnosis, treatment, and follow-up—ensuring continuity, cultural navigation, and evidence-based decision-making.
Malignant Melanoma: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Malignant Melanoma (Dermatology)
Non-Surgical / Systemic Therapy Options
*Indicated for Stage III–IV unresectable or metastatic disease, or adjuvant therapy post-resection.*
- •BRAF/MEK Inhibitors (e.g., dabrafenib + trametinib):
- *Monthly drug cost*: ¥28,000–¥35,000 ($3,900–$4,900)
- •Immune Checkpoint Inhibitors:
- Baseline labs (CBC, LFTs, TSH, LDH): ¥420 ($60) - Infusion (240 mg IV q2w): ¥12,800 per dose ($1,790) - *Dual immunotherapy* (ipilimumab + nivolumab): - Pre-infusion workup (including CT chest/abdomen/pelvis): ¥3,600 ($500) - Cycle 1–4 (ipilimumab 3 mg/kg + nivolumab 1 mg/kg): ¥42,000–¥48,000 ($5,900–$6,700)
Surgical / Procedural Options
*Stage I–II) and resectable Stage III disease.*
- •Wide Local Excision (WLE):
- *Procedure fee*: ¥4,500–¥7,200 ($630–$1,010) - *Pre-op workup*: Dermoscopy + total-body photography (¥380), pre-anesthesia assessment (¥260), ECG (¥120) → Total: ¥760 ($106)
- •Sentinel Lymph Node Biopsy (SLNB):
- *Procedure fee*: ¥8,900–¥11,500 ($1,250–$1,610) - *Pre-op lymphoscintigraphy*: ¥1,800 ($250)
- •Completion Lymphadenectomy:
- *Fee*: ¥14,200–¥18,600 (0–$2,610)
Special / Complex Condition Management
- •In-transit/Microsatellite Metastases:
- •Brain Metastases (dermatology-coordinated with neuro-oncology):
- *Systemic therapy + SRS co-management fee*: ¥3,200 ($450)
Quick Selection Guide
- •Early-stage (IA–IB), age <70, no comorbidities: WLE + SLNB ($1,880–$2,620) — optimal balance of efficacy and low morbidity.
- •Stage IIIA–IIIB, BRAF-mutant, budget-constrained: Adjuvant BRAF/MEK inhibitors ($3,900/month) — superior 3-year RFS vs. observation.
- •Stage IV, PD-L1+ or high TMB, limited metastases: Anti-PD-1 monotherapy ($1,790/dose) — lower toxicity than dual immunotherapy.
- •Elderly (>80) or severe cardiopulmonary comorbidity: Hypofractionated radiotherapy to primary site ($1,100/course) — palliative control with minimal procedural risk.
- •In-transit disease refractory to systemic therapy: ILP ($4,500–$5,750) — highest local response rate (≥80%) in limb-confined disease.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Malignant Melanoma Medical Vacation Packages
Curated transparent all-inclusive packages combining Malignant Melanoma treatment with China top medical destinations:
